Expertise in
8
conditions

Dr. Jordan D. Berlin

Gastroenterology
Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, 
Nashville, TN 
Accepting New Patients
Offers Telehealth
Expertise in
8
conditions
Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, 
Nashville, TN 

Overview

Jordan Berlin is a Gastroenterologist practicing medicine in Nashville, Tennessee.

Dr. Berlin is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Pancreatic Cancer, Colorectal Cancer, Pancreaticoduodenectomy, and Colostomy.

He is actively involved in clinical research, co-authoring 167 peer reviewed articles and participating in 28 clinical trials. Dr. Berlin is currently accepting new patients.

Graduate Institution

University Of Illinois College Of Med (Chi/peor/rock/chm-Urb)

Specialties

Gastroenterology

Licenses

Internal Medicine in TN

Hospital Affiliations

Vanderbilt University Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

Vanderbilt-Ingram Cancer Center
2220 Pierce Ave, Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

28 Clinical Trials

A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Enrollment Status: Completed
Publish Date: October 20, 2026
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Irinotecan
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: November 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase Ib/II Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment
A Phase Ib/II Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 15, 2025
Intervention Type: Other, Drug
Study Drugs: Irinotecan Hydrochloride, Veliparib
Study Phase: Phase 1
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: November 25, 2024
Intervention Type: Drug
Study Drugs: KPT-9274, Niacin ER, Nivolumab
Study Phase: Phase 1
A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: September 05, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase I/II Study to Evaluate the Safety, Efficacy, and Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Phase I/II Study to Evaluate the Safety, Efficacy, and Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Other, Drug, Biological, Device
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

167 Total Publications

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.
Journal: The New England journal of medicine
Published: March 25, 2026
Similar Doctors
Expertise in
14
conditions
Dr. Michael F. Vaezi
Gastroenterology
Expertise in
14
conditions
Dr. Michael F. Vaezi
Gastroenterology
Referral may be required

Office

1301 Medical Center Dr Ste 1660, 
Nashville, TN 
 (0.1 miles away)
615-322-7427
Languages Spoken:
English, Farsi, Turkish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Vaezi is a Gastroenterologist practicing medicine in Nashville, Tennessee. Dr. Vaezi is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Gastroesophageal Reflux Disease (GERD), Esophagitis, Achalasia, Heartburn, and Endoscopy. Dr. Vaezi is currently accepting new patients.

Expertise in
12
conditions
Dr. David M. Schwartz
Gastroenterology
Expertise in
12
conditions
Dr. David M. Schwartz
Gastroenterology
Referral may be required

Office

1301 Medical Center Dr Ste 1660, 
Nashville, TN 
 (0.1 miles away)
615-322-0128
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Schwartz is a Gastroenterologist practicing medicine in Nashville, Tennessee. Dr. Schwartz is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Crohn's Disease, Pulmonary Fibrosis, Viral Gastroenteritis, Endoscopy, and Colonoscopy. Dr. Schwartz is currently accepting new patients.

Expertise in
18
conditions
Dr. Patrick S. Yachimski
Gastroenterology
Expertise in
18
conditions
Dr. Patrick S. Yachimski
Gastroenterology
Referral may be required

Office

1301 Medical Center Dr Ste 1660, 
Nashville, TN 
 (0.1 miles away)
615-322-0128
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Patrick Yachimski is a Gastroenterologist practicing medicine in Nashville, Tennessee. Dr. Yachimski is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Barrett Esophagus, Pancreatic Pseudocyst, Neuroma Biliary Tract, Endoscopy, and Pancreatectomy. Dr. Yachimski is currently accepting new patients.

Expertise in
7
conditions
Dr. Cathy H. Eng
Gastroenterology
Expertise in
7
conditions
Dr. Cathy H. Eng
Gastroenterology
Referral may be required

Vanderbilt-Ingram Cancer Center

2220 Pierce Ave, 
Nashville, TN 
 (0.1 miles away)
615-322-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Cathy Eng is a Gastroenterologist practicing medicine in Nashville, Tennessee. Dr. Eng is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Squamous Cell Carcinoma of the Anal Canal (SCAC), Colorectal Cancer, Appendix Cancer, Hepato-Pancreato-Biliary Surgery, and Hepatectomy. Dr. Eng is currently accepting new patients.

Expertise in
14
conditions
Dr. Laura W. Goff
Gastroenterology
Expertise in
14
conditions
Dr. Laura W. Goff
Gastroenterology
Referral may be required

Vanderbilt-Ingram Cancer Center

2220 Pierce Ave, 
Nashville, TN 
 (0.1 miles away)
615-322-5000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Laura Goff is a Gastroenterologist practicing medicine in Nashville, Tennessee. Dr. Goff is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Gallbladder Adenocarcinoma, Pancreaticoduodenectomy, and Liver Embolization. Dr. Goff is currently accepting new patients.

Expertise in
11
conditions
Dr. Dana B. Cardin
Gastroenterology
Expertise in
11
conditions
Dr. Dana B. Cardin
Gastroenterology
Referral may be required

Vanderbilt-Ingram Cancer Center

2220 Pierce Ave, 
Nashville, TN 
 (0.1 miles away)
615-322-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dana Cardin is a Gastroenterologist practicing medicine in Nashville, Tennessee. Dr. Cardin is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, and Colorectal Cancer. Dr. Cardin is currently accepting new patients.

Frequently Asked Questions about Dr. Jordan D. Berlin

How do I make an appointment with Dr. Jordan D. Berlin?

You can book an appointment with Dr. Jordan D. Berlin by calling their office at 615-322-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jordan D. Berlin a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jordan D. Berlin is classified as an Elite expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jordan D. Berlin specialize in?

While Dr. Jordan D. Berlin is a Gastroenterology, they have specific expertise in Neuroendocrine Tumor, Pancreatic Cancer, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Jordan D. Berlin participate in research or clinical trials?

Yes. Dr. Jordan D. Berlin has published 167 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Dr. Jordan D. Berlin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jordan D. Berlin accept my insurance?

Dr. Jordan D. Berlin accepts most major insurance plans, including Alliant Health and Anthem BCBS. We recommend calling the office directly at 615-322-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Berlin's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile